Healthcare / Drug Manufacturers - Specialty & GenericBSE
$137.90
+2.40 (+1.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $46.8M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
20.7x
↑EV/EBITDA
7.3x
↓ROE
9.1%
↑Gross Margin
44.4%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.7%
FCF CAGR
+31.1%
FCF margin
11.9%
FCF / Net income
0.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $654.7M · net income $124.1M · FCF $78.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $654.7M | $654.7M | $695.1M | $753.9M | $622.7M |
| Net Income | $124.1M | $124.1M | $122.4M | $141.7M | $93.3M |
| EBITDA | $187.0M | $187.0M | $185.7M | $208.6M | $116.9M |
| EPS | 12.20 | 12.20 | 11.78 | 13.83 | 9.11 |
| Gross Margin | 44.4% | 44.4% | 40.9% | 42.5% | 41.0% |
| Operating Margin | 15.3% | 15.3% | 15.7% | 19.4% | 15.9% |
| Net Margin | 19.0% | 19.0% | 17.6% | 18.8% | 15.0% |
| Cash Flow | |||||
| Free Cash Flow | $78.2M | $78.2M | $44.8M | $46.8M | $34.7M |
| Returns | |||||
| ROE | 9.1% | 9.1% | 9.7% | 12.1% | 9.0% |
| Valuation | |||||
| P/E | 20.74 | 20.74 | — | — | — |
| EV/EBITDA | 7.34 | 7.34 | — | — | — |
| P/B | 1.03 | 1.03 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -5.8% | -5.8% | -7.8% | 21.1% | — |
| EPS Growth | 3.6% | 3.6% | -14.8% | 51.9% | — |
| Dividend Yield | 2.2% | 2.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
3Y implied EPS CAGR
0.1%
EPS terminal req.
$12.24
Spread vs growth
3.5%
5Y implied EPS CAGR
3.9%
EPS terminal req.
$14.81
Spread vs growth
-0.4%
10Y implied EPS CAGR
6.9%
EPS terminal req.
$23.85
Spread vs growth
-3.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.4%
Start / end P/E
12.5x → 11.3x
EPS bridge
11.78 → 12.20
Residual
-0.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.